Addiction clinics are managing concentrated kratom withdrawal the way they manage fentanyl

The percentages are the weakest number in this story. Boulder Care reported kratom patients as a share of all new patients, and STAT's account gives those figures only as percentages ^[22]. A share rises when the numerator grows, and it also rises when the denominator shrinks. The move from 3% to 14% over eleven months is a 4.7-fold increase in share ^[1][1], and it would read the same whether the clinic took in more kratom patients or fewer of everyone else.

The Massachusetts figures are counts. Myles Jen Kin's two inpatient clinics at Recovery Centers of America went from no more than one kratom admission a week last year to 10 to 20 a week ^[8][9], a tenfold to twentyfold rise on a small base ^[2]. His current number includes people for whom kratom or 7-OH is one part of a larger substance use problem ^[9], so it is not a clean count of kratom withdrawal. Last year those admissions needed "comfort meds" only ^[8]. Now, Jen Kin said, "We're basically treating it as if it's fentanyl or oxycodone or heroin" ^[11].

Ayesha Appa, Boulder Care's head of medical affairs, attributes the rise to supply, and theorized that laws revoking access are pushing people into withdrawal ^[4]. "I think we're really seeing and feeling what happens when people lose access and need to seek care in unprecedented numbers," she said ^[3]. The same article undercuts that as a full explanation: clinicians noticed similar trends before local bans took effect ^[13]. Losing a supply moves people into withdrawal on a predictable schedule. That makes supply loss a credible accelerant for a trend that started earlier.

The national series are coarser. Federal survey data has lifetime kratom use rising from around 4 million people in 2019 to 5 million in 2023, a 25% increase ^[14][4]. Poison center reports of kratom exposure over the past decade went from 258 to 3,434, roughly thirteenfold, with a sharp rise in 2025 ^[15][3]. The two windows are different and cannot be divided into a rate. Reports of harm still grew far faster than the number of people who had ever tried the leaf, and a change in what is being sold fits that pattern better than a change in how many people are buying.

The harder clinical problem is knowing what the patient took. 7-OH is often marketed as kratom, and products across the category have turned up containing compounds absent from the label plus additives such as caffeine, kava or CBD ^[17]. Phil Smyth of Milestone Treatment Center said, "The common story I get from a lot of these clients is that they didn't know really what it was" ^[18]. A self-reported history of kratom does not separate a leaf powder from a concentrated 7-OH shot ^[21].

Death records have the same problem. Of kratom-related deaths reported to the CDC over the last decade, 79% involved other substances, mainly other opioids ^[16], leaving about one in five with no second drug named ^[5].

Two providers are two providers: one national telehealth clinic and two inpatient sites in a single state, both counting the patients who walked in ^[1][9]. Those are admission counts, not an incidence rate, and no one here has counted how many people in the United States are dependent on 7-OH. It is enough to change the question asked at intake. The pharmacology is not ambiguous, since 7-OH acts directly on opioid receptors while the leaf's dominant alkaloid does not ^[6], and the DEA's unfinished threshold rule ^[7] has no bearing on what the patient in the chair is withdrawing from.